Regorafenib (Stivarga, BAY73- 4506)

DRUG2 trials

Sponsors

Bayer

Conditions

Colorectal NeoplasmsCoronavirus Disease 2019 (COVID-19)Malignant Solid TumorsSARS-CoV-2 Infection

Phase 3

Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy

CompletedNCT01853319

BayerColorectal Neoplasms

Start: 2013-07-24End: 2018-06-11Updated: 2019-04-22

Unknown Phase

An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib

CompletedNCT05594147

BayerCoronavirus Disease 2019 (COVID-19), Malignant Solid Tumors, SARS-CoV-2 Infection

Start: 2022-10-31End: 2023-04-21Updated: 2023-11-07

Related Papers

Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

BMJ Open2020-03-0114 citations